GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms

Dragana Nikolic, Manfredi Rizzo, Angelo Maria Patti, Giuseppe Montalto, Manfredi Rizzo, Brooke S. Mcadams, Francesco Cosentino, Ali A. Rizvi, Carlo Mannina

Risultato della ricerca: Article

11 Citazioni (Scopus)

Abstract

Type 2 diabetes mellitus (T2DM) is a metabolic condition with an elevated impact on cardiovascular (CV) risk. The innovative therapeutic approaches for T2DM - incretin-based therapies (IBTs), including glucagon-like peptide 1 (GLP-1) receptor agonists, have become popular and more widely used in recent years. The available scientific data from clinical studies and clinical practice highlights their beyond glucose-lowering effects, which is achieved without any increase in hypoglycaemia. The former effects include reduction in body weight, lipids, blood pressure, inflammatory markers, oxidative stress, endothelial dysfunction, and subclinical atherosclerosis, thus reducing and potentially preventing CV events. In fact, the introduction of IBTs is one of the key moments in the history of diabetes research and treatment. Such therapeutic strategies allow customization of antidiabetic treatment to each patient's need and therefore obtain better metabolic control with reduced CV risk. The aim of the present paper is to provide a comprehensive overview of the effects of GLP-1RA on various cardiometabolic markers and overall CV risk, with particular attention on recent CV outcome studies and potential mechanisms. In particular, the effects of liraglutide on formation and progression of atherosclerotic plaque and mechanisms explaining its cardioprotective effects are highlighted.
Lingua originaleEnglish
pagine (da-a)2814-2821
Numero di pagine8
RivistaDefault journal
Volume1864
Stato di pubblicazionePublished - 2018

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Molecular Biology

Cita questo

GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms. / Nikolic, Dragana; Rizzo, Manfredi; Patti, Angelo Maria; Montalto, Giuseppe; Rizzo, Manfredi; Mcadams, Brooke S.; Cosentino, Francesco; Rizvi, Ali A.; Mannina, Carlo.

In: Default journal, Vol. 1864, 2018, pag. 2814-2821.

Risultato della ricerca: Article

Nikolic, Dragana ; Rizzo, Manfredi ; Patti, Angelo Maria ; Montalto, Giuseppe ; Rizzo, Manfredi ; Mcadams, Brooke S. ; Cosentino, Francesco ; Rizvi, Ali A. ; Mannina, Carlo. / GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms. In: Default journal. 2018 ; Vol. 1864. pagg. 2814-2821.
@article{8622af9386334090a5000e8d558d1262,
title = "GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms",
abstract = "Type 2 diabetes mellitus (T2DM) is a metabolic condition with an elevated impact on cardiovascular (CV) risk. The innovative therapeutic approaches for T2DM - incretin-based therapies (IBTs), including glucagon-like peptide 1 (GLP-1) receptor agonists, have become popular and more widely used in recent years. The available scientific data from clinical studies and clinical practice highlights their beyond glucose-lowering effects, which is achieved without any increase in hypoglycaemia. The former effects include reduction in body weight, lipids, blood pressure, inflammatory markers, oxidative stress, endothelial dysfunction, and subclinical atherosclerosis, thus reducing and potentially preventing CV events. In fact, the introduction of IBTs is one of the key moments in the history of diabetes research and treatment. Such therapeutic strategies allow customization of antidiabetic treatment to each patient's need and therefore obtain better metabolic control with reduced CV risk. The aim of the present paper is to provide a comprehensive overview of the effects of GLP-1RA on various cardiometabolic markers and overall CV risk, with particular attention on recent CV outcome studies and potential mechanisms. In particular, the effects of liraglutide on formation and progression of atherosclerotic plaque and mechanisms explaining its cardioprotective effects are highlighted.",
author = "Dragana Nikolic and Manfredi Rizzo and Patti, {Angelo Maria} and Giuseppe Montalto and Manfredi Rizzo and Mcadams, {Brooke S.} and Francesco Cosentino and Rizvi, {Ali A.} and Carlo Mannina",
year = "2018",
language = "English",
volume = "1864",
pages = "2814--2821",
journal = "Default journal",

}

TY - JOUR

T1 - GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms

AU - Nikolic, Dragana

AU - Rizzo, Manfredi

AU - Patti, Angelo Maria

AU - Montalto, Giuseppe

AU - Rizzo, Manfredi

AU - Mcadams, Brooke S.

AU - Cosentino, Francesco

AU - Rizvi, Ali A.

AU - Mannina, Carlo

PY - 2018

Y1 - 2018

N2 - Type 2 diabetes mellitus (T2DM) is a metabolic condition with an elevated impact on cardiovascular (CV) risk. The innovative therapeutic approaches for T2DM - incretin-based therapies (IBTs), including glucagon-like peptide 1 (GLP-1) receptor agonists, have become popular and more widely used in recent years. The available scientific data from clinical studies and clinical practice highlights their beyond glucose-lowering effects, which is achieved without any increase in hypoglycaemia. The former effects include reduction in body weight, lipids, blood pressure, inflammatory markers, oxidative stress, endothelial dysfunction, and subclinical atherosclerosis, thus reducing and potentially preventing CV events. In fact, the introduction of IBTs is one of the key moments in the history of diabetes research and treatment. Such therapeutic strategies allow customization of antidiabetic treatment to each patient's need and therefore obtain better metabolic control with reduced CV risk. The aim of the present paper is to provide a comprehensive overview of the effects of GLP-1RA on various cardiometabolic markers and overall CV risk, with particular attention on recent CV outcome studies and potential mechanisms. In particular, the effects of liraglutide on formation and progression of atherosclerotic plaque and mechanisms explaining its cardioprotective effects are highlighted.

AB - Type 2 diabetes mellitus (T2DM) is a metabolic condition with an elevated impact on cardiovascular (CV) risk. The innovative therapeutic approaches for T2DM - incretin-based therapies (IBTs), including glucagon-like peptide 1 (GLP-1) receptor agonists, have become popular and more widely used in recent years. The available scientific data from clinical studies and clinical practice highlights their beyond glucose-lowering effects, which is achieved without any increase in hypoglycaemia. The former effects include reduction in body weight, lipids, blood pressure, inflammatory markers, oxidative stress, endothelial dysfunction, and subclinical atherosclerosis, thus reducing and potentially preventing CV events. In fact, the introduction of IBTs is one of the key moments in the history of diabetes research and treatment. Such therapeutic strategies allow customization of antidiabetic treatment to each patient's need and therefore obtain better metabolic control with reduced CV risk. The aim of the present paper is to provide a comprehensive overview of the effects of GLP-1RA on various cardiometabolic markers and overall CV risk, with particular attention on recent CV outcome studies and potential mechanisms. In particular, the effects of liraglutide on formation and progression of atherosclerotic plaque and mechanisms explaining its cardioprotective effects are highlighted.

UR - http://hdl.handle.net/10447/299148

UR - http://www.elsevier.com/locate/bbadis

M3 - Article

VL - 1864

SP - 2814

EP - 2821

JO - Default journal

JF - Default journal

ER -